FDA Nominee Califf Seeks Clinical Trial, Combo Product Reforms
This article was originally published in The Gray Sheet
President Obama nominated Robert Califf for FDA commissioner, and Senate HELP Chairman Lamar Alexander said the committee "will move promptly" to consider the nomination. If confirmed, he would be expected to lead reforms of the combination products review process, among other initiatives. However, while the initial positive response from Sen. Alexander suggests the possibility of a smooth confirmation, it certainly isn't guaranteed.
You may also be interested in...
The Senate confirmed Robert Califf as the new FDA commissioner after months of delay, giving the cardiologist, clinical trial expert and established agency official a better platform to push his priorities, which include combination product and clinical data-collection reforms, while implementing projects already under way.
Our most popular stories last month focused on tips from FDA experts on facility inspections, various legal trends, and Robert Califf's nomination to head FDA, among other topics.
Groups including Public Citizen say the Senate should reject the president's nomination of clinical trials expert and cardiologist Robert Califf as FDA commissioner due to his prior financial ties to industry. "The Gray Sheet" takes a look at his financial conflict of interest forms from former employer Duke University, which show relationships with a range of manufacturers – although more are from the pharmaceutical arena than the medical device space. But entries in Duke University’s conflict-of-interest disclosures don't always match up to those in the government's Open Payments database.